Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Ipilimumab in resected high-risk melanoma
NCT02388906Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2015
- Primary completion
- Nov 2018
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Recurrence-free Survival at 36 months. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02388906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388906.